{"id":49653,"date":"2022-10-14T17:01:44","date_gmt":"2022-10-14T15:01:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/"},"modified":"2022-10-14T17:01:44","modified_gmt":"2022-10-14T15:01:44","slug":"2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/","title":{"rendered":"2022 Hepatitis D Drugs in Development Report &#8211; Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5645037\/hepatitis-d-drugs-in-development-by-stages?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=lx8r8p&amp;utm_campaign=1762378+-+2022+Hepatitis+D+Drugs+in+Development+Report+-+Featuring+Antios+Therapeutics%2C+CN+Bio+Innovations%2C+Eiger+BioPharmaceuticals+and+Gilead+Sciences+Among+Others&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221014005313\/en\/1602419\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221014005313\/en\/1602419\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis report provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nAlbireo Pharma Inc\n<\/li>\n<li>\nAntios Therapeutics Inc\n<\/li>\n<li>\nCN Bio Innovations Ltd\n<\/li>\n<li>\nEiger BioPharmaceuticals Inc\n<\/li>\n<li>\nF. Hoffmann-La Roche Ltd\n<\/li>\n<li>\nGilead Sciences Inc\n<\/li>\n<li>\nGlobeimmune Inc\n<\/li>\n<li>\nHuahui Anjian (Beijing) Biotechnology Co Ltd\n<\/li>\n<li>\nJohnson &amp; Johnson\n<\/li>\n<li>\nMerck &amp; Co Inc\n<\/li>\n<li>\nPharmaEssentia Corp\n<\/li>\n<li>\nReplicor Inc\n<\/li>\n<li>\nRodos BioTarget GmbH\n<\/li>\n<li>\nSomaGenics Inc\n<\/li>\n<li>\nSvenska Vaccinfabriken Produktion AB\n<\/li>\n<li>\nVir Biotechnology Inc\n<\/li>\n<\/ul>\n<p>\nHepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.\n<\/p>\n<p>\n<strong>Report Highlights<\/strong>\n<\/p>\n<p>\nThe report provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\n<\/p>\n<p>\nThe Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies \/Universities \/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 1, 8 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 3 molecules, respectively.\n<\/p>\n<p>\nHepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company\/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.\n<\/p>\n<p>\n<strong>Scope<\/strong>\n<\/p>\n<ul>\n<li>\nThe pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).\n<\/li>\n<li>\nThe pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities\/research institutes based on information derived from company and industry-specific sources.\n<\/li>\n<li>\nThe pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.\n<\/li>\n<li>\nThe pipeline guide features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&amp;D brief, MoA &amp; other developmental activities.\n<\/li>\n<li>\nThe pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.\n<\/li>\n<li>\nThe pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.\n<\/li>\n<li>\nThe pipeline guide encapsulates all the dormant and discontinued pipeline projects.\n<\/li>\n<li>\nThe pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)\n<\/li>\n<\/ul>\n<p>\n<strong>Reasons to Buy<\/strong>\n<\/p>\n<ul>\n<li>\nProcure strategically important competitor information, analysis, and insights to formulate effective R&amp;D strategies.\n<\/li>\n<li>\nRecognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.\n<\/li>\n<li>\nFind and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).\n<\/li>\n<li>\nClassify potential new clients or partners in the target demographic.\n<\/li>\n<li>\nDevelop tactical initiatives by understanding the focus areas of leading companies.\n<\/li>\n<li>\nPlan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.\n<\/li>\n<li>\nFormulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.\n<\/li>\n<li>\nDevelop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.\n<\/li>\n<li>\nAdjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5645037\/hepatitis-d-drugs-in-development-by-stages?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=lx8r8p&amp;utm_campaign=1762378+-+2022+Hepatitis+D+Drugs+in+Development+Report+-+Featuring+Antios+Therapeutics%2C+CN+Bio+Innovations%2C+Eiger+BioPharmaceuticals+and+Gilead+Sciences+Among+Others&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/v4kpdo<\/a>\n<\/p>\n<p>\nSource: Global Markets Direct\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x70;&#x72;&#101;s&#x73;&#x40;&#114;e&#x73;&#x65;&#97;r&#x63;&#104;&#97;n&#x64;&#109;a&#x72;&#x6b;&#101;t&#x73;&#x2e;&#99;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#x65;&#x73;&#x73;&#x40;&#x72;&#x65;&#x73;&#x65;&#x61;&#114;&#99;&#104;&#97;&#110;&#100;&#109;arkets&#x2e;&#x63;&#x6f;&#x6d;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape. Companies Mentioned Albireo Pharma Inc Antios Therapeutics Inc CN Bio Innovations Ltd Eiger BioPharmaceuticals Inc F. &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49653","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>2022 Hepatitis D Drugs in Development Report - Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2022 Hepatitis D Drugs in Development Report - Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape. Companies Mentioned Albireo Pharma Inc Antios Therapeutics Inc CN Bio Innovations Ltd Eiger BioPharmaceuticals Inc F. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-14T15:01:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221014005313\/en\/1602419\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"2022 Hepatitis D Drugs in Development Report &#8211; Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-10-14T15:01:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\\\/\"},\"wordCount\":757,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005313\\\/en\\\/1602419\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\\\/\",\"name\":\"2022 Hepatitis D Drugs in Development Report - Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005313\\\/en\\\/1602419\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-10-14T15:01:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005313\\\/en\\\/1602419\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005313\\\/en\\\/1602419\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2022 Hepatitis D Drugs in Development Report &#8211; Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2022 Hepatitis D Drugs in Development Report - Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"2022 Hepatitis D Drugs in Development Report - Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape. Companies Mentioned Albireo Pharma Inc Antios Therapeutics Inc CN Bio Innovations Ltd Eiger BioPharmaceuticals Inc F. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-14T15:01:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221014005313\/en\/1602419\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"2022 Hepatitis D Drugs in Development Report &#8211; Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others &#8211; ResearchAndMarkets.com","datePublished":"2022-10-14T15:01:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/"},"wordCount":757,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221014005313\/en\/1602419\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/","name":"2022 Hepatitis D Drugs in Development Report - Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221014005313\/en\/1602419\/21\/logo.jpg","datePublished":"2022-10-14T15:01:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221014005313\/en\/1602419\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221014005313\/en\/1602419\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/2022-hepatitis-d-drugs-in-development-report-featuring-antios-therapeutics-cn-bio-innovations-eiger-biopharmaceuticals-and-gilead-sciences-among-others-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"2022 Hepatitis D Drugs in Development Report &#8211; Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49653"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49653\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}